News

One-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma.

Learn about the latest updates from The Association for Research in Vision and Ophthalmology for 2017 and beyond.

The bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.

Sabin Dang, MD, didn’t have as clear cut of a journey to the ophthalmic world as many would expect. While today he spends his working hours improving visual outcomes of patients at Ophthalmic Consultants of Boston, a few years ago you would have found him creating coding software in his IT consulting company to help businesses grow.

A new trabecular meshwork excision blade takes a new approach in IOP reduction.

Ceeable, a web-based, mobile digital technology designed to detect early-stage eye diseases-an innovation that can help shape 21st century medicine-was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.

Uveitis presents particular problems for ophthalmologists. Inflammation inside the eye can occur from so many causes that the diagnosis often requires painstaking, time-consuming investigation. As researchers have learned more about the disease, the possible etiologies and treatments have multiplied.

From the silent auction, art sales, and an opera performance, the 2016 Glaucoma 360 gala was one not to be soon forgotten.

Rishi Singh, MD, explains a case with a patient with moderately severe DME.

Santen Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.

Hear about the case, view the slides, and vote on your responses.

Change is an inside job. Are you unhappy with your practice’s growth? Take the often overlooked option of offensive time management. Actively shape your day by establishing what I like to call selective control.

It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.

A portable non-mydriatic fundus camera was found useful in grading cup-to-disc ratio as part of glaucoma screening compared with a standard tabletop mydriatic fundus camera.

A visit to two innovative optical shops reveals differing portraitures of providing better customer experience and increasing capture rate.

Cataract surgery with or without intravenous sedation can be a factor in the clinical experience. Moving to sublingual sedation may be the next step in safety and comfort for a demanding patient demographic.

Delayed patient presentation, compounded by problems relating to insufficient resources and lack of follow-up, explain why pediatric cataract remains an important cause of visual impairment in Tunisia.

The combination of phenylephrine and ketorolac helped maintain pupil diameter and lowered postoperative pain compared with placebo in patients having cataract surgery in two pooled phase III studies.

Surgical draping for ophthalmic surgery has never been quick or easy-until now. A new drape design allows the surgeon or scrub nurse to fully drape the patient in seconds.

Intracameral administration of the fixed combination of phenylephrine and ketorolac injection 1%/0.3% (Omidria, Omeros) during cataract surgery is safe and effective for maintaining pupil dilation, and minimizes the need for a pupil expansion device, according to the findings of a retrospective study conducted by Frank A. Bucci, Jr., MD.

The U.S. IDE clinical trial of the investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott Medical Optics) found that the implant delivered a full range of uncorrected vision and minimized or eliminated the need for spectacle wear in most patients.

Glaucoma is more likely to develop in children who undergo cataract surgery when they are 6 weeks or younger.

In a multicenter trial including 162 eyes undergoing cataract surgery with implantation of a variety of IOL types, use of intraoperative aberrometry to guide IOL spherical power selection minimized residual refractive error.

Results of two phase III trials with dexamethasone intracanalicular depot are highlighted. Both trials met the endpoints for postsurgical pain, but only one trial met the endpoints for postoperative inflammation

Patients with keratoconus pose unique challenges with IOL calculations.

By just about anybody's definition of success, ophthalmologists are successful: intelligent, well-paid, able to make people’s lives better and held in high esteem by the public. Not to mention good-looking. So they must be happy-right? Not necessarily.

An approach is described for completing cortex removal and IOL implantation after intraoperative 180° zonular dialysis.

Ophthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients-and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.

Watch as Ben Wucher, researcher at University of Rochester Medical Center, summarizes his research titled, "Clinical keratitis isolates of Pseudomonas aeruginosa develop resistant biofilms."

Alcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.